Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer (IMPACTO)

March 19, 2026 updated by: Centre Hospitalier Régional d'Orléans

Impact of Hospital Pharmacist on Drug Management in Patients With Bronchopulmonary Cancer Treated by Chemotherapy and/or Immunotherapy or Oral Targeted Therapy

This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients (only questionnaires) with bronchopulmonary cancer treated by Chemotherapy and/or Immunotherapy or Oral targeted therapy. The primary objective of the study is to evaluate the number of unscheduled consultations/hospitalizations during 6 months.

Study Overview

Status

Completed

Conditions

Intervention / Treatment

Detailed Description

Currently, several treatments can be used for bronchopulmonary cancers: targeted oral therapy (OCT), oral chemotherapy, iv chemotherapy, iv immunotherapy. These therapies are rather unknown to community pharmacy and induce several adverse effects and drug interactions. These treatments require collaboration between different professionals (community and hospital pharmacists) in order to allow follow up and security in patient supportive care.

In our context of shortage of care staff, with a polymedicated and elderly population, we would like to assess the impact of hospital pharmacist in the drug management for patient with bronchopulmonary cancers treated by these therapies.

Other French studies (Lille, Angers, Tours) involving hospital pharmacists were carried out and aimed to evaluate the number of pharmaceutical interventions carried out without assessing the impact on the patient. In addition, no study concerns the Center Val de Loire region.

The aim of the study is to impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.

This is a prospective, non-interventional study to evaluate impact of hospital pharmacist on drug management in patients with bronchopulmonary cancer. Participants will be included after being informed and after obtaining no opposition to participate. Data collection sheet will be performed by hospital pharmacist at inclusion. Participants will be treated according to standard of care for cancer treatment. An interview will be performed 1 month, 3 months and 6 months after inclusion between hospital pharmacist and participant to obtain information's on cancer treatments (questionnaires). These interviews will be performed by phone or when the patient comes to the hospital for a follow-up consultation as part of the treatment of his cancer (standard of care).

A total of 60 participants will be included in this study based on 1) the number of patients received a novel cancer treatment in the center during 12 months and 2) considered eligibility criteria, pharmacist availability and patients consent.

Study Type

Observational

Enrollment (Actual)

60

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Orléans, France, 45067
        • CHU d'Orléans

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Sampling Method

Non-Probability Sample

Study Population

Patients with bronchopulmonary cancer who received a new treatment with oral targeted therapy, chemotherapy or immunotherapy.

Description

Inclusion Criteria:

  1. Male or female ≥ 18 years
  2. Patient without cognitive impairments
  3. Patient with bronchopulmonary cancer
  4. Patient treated by chemotherapy, immunotherapy or oral targeted therapy

Exclusion Criteria:

  1. Patient informed and opposed to participate
  2. Language barrier and lack of translator
  3. Patient under guardianship, curatorship or deprived of liberty
  4. Pregnant or breastfeeding women
  5. Participation in any drug clinical drug trials
  6. Patient with no insurance

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Impact of hospital pharmacist (interview) on the number of unscheduled consultations/hospitalizations.
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of unscheduled consultations or hospitalizations during the follow up phase
From enrolment to the end of the follow up phase (6 months)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Impact of hospital pharmacist (interview) on cancelled consultations/hospitalizations rate
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of cancelled consultations/hospitalizations
From enrolment to the end of the follow up phase (6 months)
Impact of hospital pharmacist (interview) on adverse effects
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of adverse effects (follow up phase of 6 months)
From enrolment to the end of the follow up phase (6 months)
Impact of hospital pharmacist (interview) on adverse effects leading to interrupted or withdrawn treatment
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of adverse effects leading to interrupted or withdrawn treatment
From enrolment to the end of the follow up phase (6 months)
Impact of hospital pharmacist on pharmaceutical intervention
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of pharmaceutical interventions (eg. inappropriate prescription, drug interactions)
From enrolment to the end of the follow up phase (6 months)
Impact of hospital pharmacist (interview) on treatment observance (number of dispensation)
Time Frame: From enrolment to the end of the follow up phase (6 months)
Number of treatment dispensation
From enrolment to the end of the follow up phase (6 months)
Impact of hospital pharmacist (interview) on treatment observance (gap between dispensation)
Time Frame: From enrolment to the end of the follow up phase (6 months)
Gap between each treatment dispensation
From enrolment to the end of the follow up phase (6 months)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Centre Hospitalier Régional d'Orléans

Investigators

  • Principal Investigator: Catherine DA VIOLANTE, Dr, CHU d'Orléans

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

June 25, 2024

Primary Completion (Actual)

June 23, 2025

Study Completion (Actual)

December 31, 2025

Study Registration Dates

First Submitted

June 3, 2024

First Submitted That Met QC Criteria

June 19, 2024

First Posted (Actual)

June 24, 2024

Study Record Updates

Last Update Posted (Actual)

March 20, 2026

Last Update Submitted That Met QC Criteria

March 19, 2026

Last Verified

March 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CHRO-2023-12

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

No

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Patients With Bronchopulmonary Cancer

Clinical Trials on Questionnaires and data collection sheet

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Ireland

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe